NASDAQ : CUVL
Clinuvel Pharmaceuticals Limited — Key statistics
Australia
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 249.47M |
| Enterprise Value | 73.96M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 27, 2026 |
| Ex-Dividend Date | Sep 8, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 50.43M |
| Shares Change (YoY) | +0.73% |
| Shares Change (QoQ) | +0.51% |
| Owned by Insiders (%) | 10.00% |
| Owned by Institutions (%) | 23.29% |
| Float | 42.06M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 10.53 |
| Forward PE | 10.37 |
| PS Ratio | 3.84 |
| Forward PS | 3.86 |
| PB Ratio | 1.32 |
| P/TBV Ratio | 1.32 |
| P/FCF Ratio | 10.12 |
| P/OCF Ratio | 9.68 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 3.15 |
| EV / Sales | 1.14 |
| EV / EBITDA | 2.60 |
| EV / EBIT | 2.64 |
| EV / FCF | 3.00 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 14.81 |
| Quick Ratio | 14.34 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.05 |
| Debt / FCF | 0.05 |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 13.21% |
| Return on Assets (ROA) | 8.94% |
| Return on Invested Capital (ROIC) | 126.71% |
| Return on Capital Employed (ROCE) | 14.69% |
| Weighted Average Cost of Capital (WACC) | 7.39% |
| Revenue Per Employee | $4.07M |
| Profits Per Employee | $1.47M |
| Employee Count | 16 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 2.01 |
Taxes
| Measure | Value |
|---|
| Income Tax | 9.51M |
| Effective Tax Rate | 28.84% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.58 |
| 52-Week Price Change | -33.20% |
| 50-Day Moving Average | 5.78 |
| 200-Day Moving Average | 6.92 |
| Relative Strength Index (RSI) | 33.75 |
| Average Volume (20 Days) | 5,818 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 15,683 |
| Short Previous Month | 26,443 |
| Short % of Shares Out | 0.03% |
| Short % of Float | 0.04% |
| Short Ratio (days to cover) | 1.72 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 65.05M |
| Gross Profit | 54.11M |
| Operating Income | 28.04M |
| Pretax Income | 32.97M |
| Net Income | 23.46M |
| EBITDA | 28.44M |
| EBIT | 28.04M |
| Earnings Per Share (EPS) | $0.47 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 174.37M |
| Total Debt | 1.34M |
| Net Cash | 173.03M |
| Net Cash Per Share | $3.43 |
| Equity (Book Value) | 188.78M |
| Book Value Per Share | 3.74 |
| Working Capital | 183.61M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 25.76M |
| Capital Expenditures | -1.12M |
| Depreciation & Amortization | 402,442 |
| Net Borrowing | -166,564 |
| Free Cash Flow | 24.64M |
| FCF Per Share | $0.49 |
Margins
| Measure | Value |
|---|
| Gross Margin | 83.18% |
| Operating Margin | 43.11% |
| Pretax Margin | 50.69% |
| Profit Margin | 36.07% |
| EBITDA Margin | 43.72% |
| EBIT Margin | 43.11% |
| FCF Margin | 37.55% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $0.03 |
| Dividend Yield | 0.58% |
| Dividend Growth (YoY) | 7.89% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 6.04% |
| FCF Payout Ratio | 5.77% |
| Buyback Yield | -0.73% |
| Shareholder Yield | -0.15% |
| Earnings Yield | 9.50% |
| FCF Yield | 9.88% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 12.64% |
| EPS Growth Forecast (3Y) | 13.27% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 17.18 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |